Download this infographic to learn more.
With oncology representing nearly 40% of global pharma licensing deals and over $25 billion in annual payments, timing is critical—especially as licensing windows shrink due to policy changes like the IRA. Sponsors are increasingly focused on earlier-stage assets and expanding clinical plans to global regions.
Access this exclusive content to learn about key strategic approaches for speeding up licensing readiness, including:
Don’t miss out! See how implementing the right tactics can compress timelines, command higher upfront payments, and facilitate smoother post-deal transitions.
Offered Free by: Premier Research
See All Resources from: Premier Research





